Rocket Pharmaceuticals, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Rocket Pharmaceuticals, Inc. (RCKT) had Deferred Tax Assets, Operating Loss Carryforwards of $78.74 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $78.74M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $67.59M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $45.31M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $33.72M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $78.74M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $67.59M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $45.31M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $33.72M 10-K · filed 2025-02-27 | |
| 2021-12-31 | $26.79M 10-K · filed 2024-02-27 | |
| 2020-12-31 | $21.36M 10-K · filed 2023-02-28 | $42.61M 10-K · filed 2021-03-01 |
| 2019-12-31 | $2.52M 10-K · filed 2022-02-28 | $20.99M 10-K · filed 2020-03-06 |
| 2018-12-31 | $27.82M 10-K · filed 2021-03-01 | $28.40M 10-K · filed 2019-03-08 |
| 2017-12-31 | $1.62M 10-K · filed 2019-03-08 | $37.25M 10-K · filed 2018-03-07 |
| 2016-12-31 | $458.00K 10-K · filed 2019-03-08 | $43.77M 10-K · filed 2017-03-16 |
| 2015-12-31 | $35.86M 10-K · filed 2017-03-16 | |
| 2014-12-31 | $30.90M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |